Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research underway in the Department of Engineering Science’s Cerebral Haemodynamics Group, headed up by Professor Stephen Payne, is changing our understanding of blood flow around the brain. A new Oxford Science Blog explains how this could speed up the arduous process of bringing stroke drugs to market.

There are over 1.2 million stroke survivors in the UK, with 100,000 strokes happening in the UK each year. That’s the equivalent of one stroke every five minutes. They are also the leading cause of disability in the Western world.

Our research has two main questions. Firstly, can we model blood and oxygen transport in the entire human brain, across the billions of blood vessels present? And secondly, can we run in-silico clinical trials (that is, trials performed entirely on a computer) of stroke and stroke treatment?

This is what we are tackling as part of a Horizon 2020 project (In-Silico Trials for Treatment of Acute Ischaemic Stroke) alongside European research collaborators from 10 other institutes, including radiotherapists, clinicians, academics, and industrial partners.

Read more (University of Oxford website)

Find out more about Brain Awareness Week at Oxford.

This article was published to mark Brain Awareness Week, a global campaign running from 11-17 March. 

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.